ArticleScientific reports2026
Therapeutic potential of asparagus polysaccharide in bladder cancer treatment via modulation of PI3K/AKT/mTOR signaling.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Bladder cancer (BCa) is one of the most prevalent malignant tumors worldwide, with high incidence and recurrence rates, underscoring the urgent need for safe and effective therapeutic strategies. Recently, asparagus polysaccharide (ASP) has attracted attention for its diverse bioactivities, including anticancer, anti-inflammatory, and low-toxicity properties. However, its effects on BCa remain poorly understood. Objective This study aims to investigate the effects of ASP on bladder cancer cells and to elucidate the underlying molecular mechanisms. Methods The effects of ASP on T24 and 5637 bladder cancer cells were assessed using the cell counting Kit-8 (CCK-8), colony formation, wound healing, transwell invasion, TUNEL, and ROS assays. Western blot analysis was performed to assess apoptosis-related proteins (Bax, cleaved Caspase-3, Bcl-2) and key proteins of the PI3K/AKT/mTOR pathway. Additionally, IGF-1, a pathway activator, was used to explore ASP's mechanistic effects. Results ASP inhibited cell proliferation, migration, and invasion in a dose-dependent manner, and also induced apoptosis and elevated ROS levels. Western blot analysis revealed ASP-mediated downregulation of PI3K/AKT/mTOR signaling, as evidenced by reduced phosphorylation of PI3K, AKT, and mTOR. Co-treatment with IGF-1 partially reversed these effects, restoring phosphorylation of PI3K/AKT/mTOR components and cellular migration and invasion, indicating ASP's anticancer activity was mediated through this pathway. Conclusion ASP exerted anticancer effects in BCa by inhibiting PI3K/AKT/mTOR pathway, suppressing proliferation and invasion, and inducing apoptosis. These findings underscore ASP's potential as a novel therapeutic agent for bladder cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.